Diabetic Retinopathy, Diabetes Mellitus, Retinal Microvascular Disease
Conditions
Keywords
Diabetic Retinopathy, Endocan, Alarin, Galanin-Like Peptide, Optical Coherence Tomography, Retinal Nerve Fiber Layer
Brief summary
This prospective cross-sectional study aims to evaluate the association between serum endocan, alarin, and galanin-like peptide levels and the stages of diabetic retinopathy (DR), as well as their relationship with optical coherence tomography (OCT) findings. A total of 120 participants will be included: 30 patients without diabetic retinopathy, 30 with non-proliferative diabetic retinopathy, 30 with proliferative diabetic retinopathy, and 30 healthy control subjects. In addition to routine preoperative blood sampling, an additional 5 mL of venous blood will be collected for biomarker analysis using ELISA. Macular and peripapillary retinal nerve fiber layer measurements will be obtained using OCT. Serum biomarker levels will be compared across DR stages and analyzed for correlation with OCT parameters.
Interventions
PROCEDUREVenous Blood Sampling
Collection of 5 mL of venous blood in addition to routine preoperative sampling for the measurement of serum endocan, alarin, and galanin-like peptide levels using ELISA.
PROCEDUREOptical Coherence Tomography (OCT)
Non-invasive optical coherence tomography imaging of the macula and peripapillary retinal nerve fiber layer using a Canon OCT device for structural retinal assessment.
Sponsors
Elazıg Fethi Sekin Sehir Hastanesi
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
40 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Adults aged 40 to 70 years. * Diagnosis of diabetes mellitus (for diabetic groups). * For control group: absence of diabetes mellitus and no retinal or optic nerve pathology.
Exclusion criteria
* Presence of systemic or ocular inflammatory disease. * Any ocular disease other than diabetic retinopathy that may affect the retina or optic nerve.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Serum Endocan Level | At baseline (preoperative blood sampling) | Serum endocan concentration measured using ELISA and compared across diabetic retinopathy stages. |
| Serum Alarin Level | At baseline | Serum alarin concentration measured by ELISA and analyzed according to diabetic retinopathy severity. |
| Serum Galanin-Like Peptide Level | At baseline | Serum galanin-like peptide concentration measured using ELISA and compared between study groups. |
Countries
Turkey (Türkiye)
Outcome results
None listed